Targeting the dynamics of skin cell formation in atopic dermatitis
Official title: Toward therapeutic targeting of liquid-liquid phase separation dynamics in skin
Funded at Emory University · NIH-11063197 · Data updated 2026-11-12
This study is looking into how a protein called filaggrin affects the skin barrier in people with atopic dermatitis, hoping to find new ways to help improve treatments for this common skin condition in both kids and adults.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | April 3, 2023 |
| Project end | April 2, 2026 |
| Funding year | 2025 |
| Award (this year) | $48,974 |
| NIH project number | 5F31AR081697-03 |
| Project ID | NIH-11063197 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals of all ages suffering from atopic dermatitis or related chronic inflammatory skin conditions.
✕Less likely to help
Patients with skin conditions unrelated to atopic dermatitis may not benefit from this research.
What this research studies
This research investigates the mechanisms behind atopic dermatitis, a common skin condition affecting both children and adults. It focuses on the role of a protein called filaggrin in skin barrier formation and how its dysfunction can lead to skin issues. By studying the behavior of keratohyalin granules, which are essential for skin cell differentiation, the research aims to uncover new therapeutic targets that could improve treatment options for patients with atopic dermatitis.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance skin barrier function and alleviate symptoms of atopic dermatitis.
How similar studies have gone: Previous research has shown promising results in targeting skin barrier dysfunctions, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Avecilla, Alexa Regina Chua — Emory University
- Study coordinator: Avecilla, Alexa Regina Chua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.